GlassScriptPhysician profile
Mark Andrew Walshauser
NPI 1306020664
$23,791.02
in general payments reported to CMS, 2019-2025
69 companies · $2,101 in 2025
The $2,101 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,996 · 2020: $3,426 · 2021: $855 · 2022: $2,835 · 2023: $2,313 · 2024: $9,265 · 2025: $2,101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,996 · Consulting Fee: $6,484 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,996.21 |
| Consulting Fee | $6,484.00 |
| Education | $199.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $3,832.62 | 2023-2024 | Libtayo |
| E.R. Squibb & Sons, L.L.C. | $2,960.67 | 2019-2025 | Opdivo, Opdualag, Pomalyst |
| Beigene USA, INC. | $2,448.94 | 2023-2024 | Brukinsa |
| Novartis Pharmaceuticals Corporation | $1,268.34 | 2019-2025 | |
| Pfizer INC. | $1,229.81 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $942.79 | 2019-2025 | Imfinzi, Enhertu, Lynparza |
| Janssen Biotech, INC. | $799.82 | 2019-2025 | Rybrevant, Talvey, Tecvayli |
| Merck Sharp & Dohme LLC | $754.12 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Genzyme Corporation | $612.11 | 2019-2025 | |
| Genentech USA, INC. | $500.32 | 2019-2025 | Polivy, Lunsumio, Columvi |
| Bayer Healthcare Pharmaceuticals INC. | $485.42 | 2019-2025 | |
| Amgen INC. | $451.96 | 2019-2023 | Kyprolis, Blincyto, Mvasi |
| Beigene, LTD. | $450.00 | 2020 | |
| Exelixis INC. | $431.27 | 2019-2025 | Cabometyx |
| Abbvie INC. | $362.35 | 2019-2025 |
Show all 69 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $360.03 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Cardinal Health 108 LLC | $350.82 | 2024-2025 | |
| Seagen INC. | $334.42 | 2019-2025 | Tukysa |
| Gilead Sciences, INC. | $333.64 | 2019-2025 | Trodelvy |
| Foundation Medicine, INC. | $323.61 | 2019-2023 | |
| Incyte Corporation | $310.75 | 2019-2025 | Monjuvi, Pemazyre, Jakafi |
| Emd Serono, INC. | $307.83 | 2019-2025 | Bavencio, Tepmetko |
| Takeda Pharmaceuticals U.S.A., INC. | $300.75 | 2019-2025 | Iclusig, Fruzaqla, Alunbrig |
| Asd Specialty Healthcare, LLC | $289.63 | 2022-2024 | |
| Astellas Pharma US INC | $284.20 | 2019-2025 | Xospata, Vyloy |
| Pharmacyclics LLC, An Abbvie Company | $258.88 | 2019-2023 | Imbruvica |
| US Oncology Corporate, INC. | $217.99 | 2024 | |
| Agios Pharmaceuticals, INC. | $186.69 | 2019 | |
| Genmab U.S., INC. | $173.47 | 2023-2024 | Epkinly, Tivdak |
| Lilly USA, LLC | $161.68 | 2019-2022 | |
| Rigel Pharmaceuticals, INC. | $161.17 | 2019-2024 | Rezlidhia, Tavalisse |
| Aveo Pharmaceuticals, INC. | $159.90 | 2022-2025 | |
| Eisai INC. | $131.18 | 2019-2022 | |
| Adaptive Biotechnologies Corporation | $128.40 | 2022-2025 | Clonoseq |
| Array Biopharma INC | $126.80 | 2021-2025 | Mektovi, Braftovi, Lorbrena |
| Glaxosmithkline, LLC. | $92.73 | 2022-2025 | Ojjaara, Zejula, Jemperli |
| Servier Pharmaceuticals LLC | $89.86 | 2021-2025 | |
| Clovis Oncology, INC. | $86.75 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $85.08 | 2019-2021 | |
| Sobi, INC | $77.35 | 2021-2024 | |
| Daiichi Sankyo INC. | $74.28 | 2019-2024 | Injectafer |
| Alexion Pharmaceuticals, INC. | $67.36 | 2019-2025 | Ultomiris |
| Deciphera Pharmaceuticals INC. | $62.44 | 2021-2025 | Qinlock |
| G1 Therapeutics, INC. | $57.05 | 2022-2023 | Cosela |
| Kite Pharma, INC. | $54.66 | 2021-2023 | |
| Karyopharm Therapeutics INC. | $44.36 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.82 | 2023-2025 | Gilotrif |
| Regeneron Healthcare Solutions, INC. | $40.06 | 2022-2024 | Libtayo |
| Tersera Therapeutics LLC | $39.03 | 2023-2025 | Zoladex |
| Kyowa Kirin, INC. | $34.23 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $33.86 | 2019-2020 | |
| Mylan Institutional INC. | $32.42 | 2019-2022 | |
| Adc Therapeutics America, INC. | $31.99 | 2022-2023 | |
| Novocure INC. | $31.38 | 2021-2025 | Optune Lua (Novottf-200t) |
| Janssen Pharmaceuticals, INC | $25.57 | 2019 | |
| Morphosys, US INC. | $23.47 | 2021 | |
| Amag Pharmaceuticals, INC. | $21.71 | 2019 | |
| Tesaro, INC. | $20.39 | 2019 | |
| Taiho Oncology, INC. | $20.22 | 2019 | |
| Blueprint Medicines Corporation | $20.15 | 2023 | Ayvakit |
| Corcept Therapeutics | $19.65 | 2025 | Korlym |
| Spectrum Pharmaceuticals INC. | $19.40 | 2025 | Rolvedon |
| Pharmacosmos Therapeutics INC. | $18.94 | 2024 | Monoferric |
| Otsuka America Pharmaceutical, INC. | $18.36 | 2019 | |
| Stemline Therapeutics INC. | $16.53 | 2023 | Orserdu |
| Verastem, INC. | $16.07 | 2019 | |
| Puma Biotechnology, INC. | $14.99 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $13.34 | 2022 | |
| Pharmaessentia USA Corporation | $13.14 | 2023 | Besremi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Walshauser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.